Association between autophagy and inflammation in patients with rheumatoid arthritis receiving biologic therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Association between autophagy and inflammation in patients with rheumatoid arthritis receiving biologic therapy ; volume:20 ; number:1 ; day:5 ; month:12 ; year:2018 ; pages:1-11 ; date:12.2018
Arthritis Research & Therapy ; 20, Heft 1 (5.12.2018), 1-11, 12.2018
- Urheber
-
Chen, Yi-Ming
Chang, Chun-Yu
Chen, Hsin-Hua
Hsieh, Chia-Wei
Tang, Kuo-Tung
Yang, Meng-Chun
Lan, Joung-Liang
Chen, Der-Yuan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-018-1763-0
- URN
-
urn:nbn:de:101:1-2019012322460755397744
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chen, Yi-Ming
- Chang, Chun-Yu
- Chen, Hsin-Hua
- Hsieh, Chia-Wei
- Tang, Kuo-Tung
- Yang, Meng-Chun
- Lan, Joung-Liang
- Chen, Der-Yuan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
Autophagy and inflammation
Experiences of mobility for people living with rheumatoid arthritis who are receiving biologic drug therapy: implications for podiatry services
Administration costs of intravenous biologic drugs for rheumatoid arthritis
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
Vaccination in Patients with Rheumatoid Arthritis Receiving Immunotherapies
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Analysis of biologic therapy in rheumatoid arthritis in a southern Spanish hospital population
Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry
Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
Autophagy and inflammation
Experiences of mobility for people living with rheumatoid arthritis who are receiving biologic drug therapy: implications for podiatry services
Administration costs of intravenous biologic drugs for rheumatoid arthritis
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
Vaccination in Patients with Rheumatoid Arthritis Receiving Immunotherapies
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Analysis of biologic therapy in rheumatoid arthritis in a southern Spanish hospital population
Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry
Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
Autophagy and inflammation
Experiences of mobility for people living with rheumatoid arthritis who are receiving biologic drug therapy: implications for podiatry services
Administration costs of intravenous biologic drugs for rheumatoid arthritis
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
Vaccination in Patients with Rheumatoid Arthritis Receiving Immunotherapies
Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
Analysis of biologic therapy in rheumatoid arthritis in a southern Spanish hospital population